目的:DRP1和OPA1在线粒体融合和分裂中起重要作用。然而,DRP1和OPA1扩增在线粒体认知障碍中的作用尚未见报道.本研究旨在探讨DRP1和OPA1与认知功能障碍风险的关系。
方法:在本研究中,纳入连云港市第二人民医院2020年9月至2021年1月收治的45例老年糖尿病患者。将患者分为正常组,轻度认知障碍组和痴呆组采用MMSE评分,比较3组患者的临床特点。通过ΔΔCT计算两个基因\'DNA的扩增倍数,并定义为2-K。Spearman等级相关性用于分析患者\'DRP1和OPA1以及AD8和MoCA评分的DNA扩增倍数之间的相关性。使用接收器操作特征(ROC)曲线评估DRP1和OPA1的DNA扩增倍数预测糖尿病认知障碍临床结局的敏感性和特异性。采用多因素logistic回归分析DRP1和OPA1的DNA扩增因子与认知功能的关系。
结果:与正常组相比,痴呆组和MCI组的DRP1(2-K)和OPA1(2-K)明显升高和降低(P≤0.001)。DRP1的DNA扩增因子与AD8评分呈正相关,与MoCA评分呈负相关(P<0.001)。OPA1的DNA扩增因子与MoCA评分呈正相关(P=0.0002)。ROCs分析表明,OPA1的DNA扩增因子对痴呆有较高的预测价值(P<0.0001),与DRP1联合使用时具有更高的预测价值。多因素logistic回归结果显示,DRP1中DNA扩增增加与痴呆风险增加相关(OR1.149;95CI,1.035-1.275),OPA1中DNA扩增增加与MCI(OR0.004;95CI,0.000-0.251)和痴呆(OR0.000;95CI,0.000-0.134)风险降低相关.
结论:DRP1和OPA1的DNA扩增倍数与老年患者痴呆的风险相关,可能作为潜在的生物标志物。
DRP1 and OPA1 play important roles in mitochondrial fusion and fission. However, the role of DRP1 and OPA1 amplification in mitochondrial cognitive impairment has not been reported. This study aimed to investigate the relationship between DRP1 and OPA1 and the risk of cognitive impairment.
In this study, 45 elderly patients with diabetes admitted to the Lianyungang Second People\'s Hospital from September 2020 to January 2021 were included. The patients were divided into normal group, mild cognitive impairment group and dementia group by using MMSE score, and the clinical characteristics of the three groups were compared. The amplification multiples of the two genes\' DNA were calculated by ΔΔCT and defined as 2- K. Spearman rank correlation was used to analyze the correlation between the DNA amplification multiples of patients\' DRP1 and OPA1 and AD8 and MoCA scores. The sensitivity and specificity of DNA amplification multiples of DRP1 and OPA1 to predict clinical outcomes of diabetic cognitive impairment were evaluated using Receiver operator characteristic (ROC) curves. Multiple logistic regression was used to evaluate the relationship between DNA amplification factor of DRP1 and OPA1 and cognitive function.
DRP1(2- K) and OPA1(2- K) significantly increased and decreased in dementia and MCI groups compared with the normal group (P ≤ 0.001). The DNA amplification factor of DRP1 was positively correlated with AD8 score and negatively correlated with MoCA score (P < 0.001). The DNA amplification factor of OPA1 was positively correlated with the MoCA score (P = 0.0002). Analysis of ROCs showed that the DNA amplification factor of OPA1 had a higher predictive value for dementia (P < 0.0001), and that it had a higher predictive value when used in combination with DRP1. Multiple logistic regression results showed that increased DNA amplification in DRP1 was associated with increased risk of dementia (OR 1.149;95%CI,1.035-1.275), and increased DNA amplification in OPA1 was associated with decreased risk of MCI (OR 0.004;95%CI,0.000-0.251) and dementia (OR 0.000;95%CI,0.000-0.134).
DNA amplification multiples of DRP1 and OPA1 are associated with the risk of dementia in elderly patients and may serve as potential biomarkers.